Anonymous
Guest
Anonymous
Guest
Pfizer's patents on Geodon expire on March 2, 2012.
Pfizer's patents on Geodon expire on March 2, 2012.
Pfizer's patents on Geodon expire on March 2, 2012.
So funny how upper mgmt thinks CUE is going to miraculously improve Geodon Mkt Share. Psychiatrists are STARVING for a new study of some kind. They are not idiots. They realize that these stupid CUE slides we are showing them are the same dumb old data from 1999. I don't care how good a salesman you are. Doctors lose respect for reps who pretend data from 10 yrs ago is new.
Earth to Mgmt: Instead of spending millions and millions on CUE, you should have invested in an SSRI Augmentation indication. Abilify is a horrible drug. How did they get more indications than Geodon when they entered the market several years later? Doctors don't even like Abilify. Yet they prescribe it 4X more than Geodon.
This is not rocket science.
Schiz represents 1% of atypical antipsychotic market. Bipolar 1 represents less than 5% of mkt.
Bipolar 2 + Tx refractory depression + Insomnia represent 70 - 90% of atypical mkt.
oh yea and we are BID, must be dosed w/ food, and have a bolded cardiovascular warning that nobody else has.
So funny how upper mgmt thinks CUE is going to miraculously improve Geodon Mkt Share. Psychiatrists are STARVING for a new study of some kind. They are not idiots. They realize that these stupid CUE slides we are showing them are the same dumb old data from 1999. I don't care how good a salesman you are. Doctors lose respect for reps who pretend data from 10 yrs ago is new.
Earth to Mgmt: Instead of spending millions and millions on CUE, you should have invested in an SSRI Augmentation indication. Abilify is a horrible drug. How did they get more indications than Geodon when they entered the market several years later? Doctors don't even like Abilify. Yet they prescribe it 4X more than Geodon.
This is not rocket science.
Schiz represents 1% of atypical antipsychotic market. Bipolar 1 represents less than 5% of mkt.
Bipolar 2 + Tx refractory depression + Insomnia represent 70 - 90% of atypical mkt.
oh yea and we are BID, must be dosed w/ food, and have a bolded cardiovascular warning that nobody else has.
Who is starving for new data? Doctors? I think you mean YOU are. Data that's several years old doesn't suddenly become bad data. The real question is how long does the data stand up. Regarding less spending on CUE and more on new indications...did you ever think that maybe the drug just doesn't work in the same areas that other APs do? I'm thinking that some of the sales people need to look in the mirror. When is the last time you actually sold the drug's efficacy? Docs don't write AP's first line because they don't cause weight gain. Take a look at Siroquel. Drug couldn't be more sedating....but they use it b/c it's perceived to WORK. Same thing with Zyprexa. Despite major se's use it b/c they perceive it work!
I'm down in South West Florida and I have seen the negative side effects of this drug and it is horrible, mainly QT prolongation, and seizures. I actually think Abilify is much better, but don't tell anyone. Just tired of it all.
GEODON never became a major blockbuster pill with only 1 billion in sales. It will have even more competition with generic RISPERDAL, SAPHRIS, and FANAPT entering the market.
Try convincing all the DOCS on the West Coast of Florida to use this crap. What a joke glad it going away.